- Liquid biopsy company Angle said it had agreed to source probe kits from global healthcare group Abbott to assist in its cancer analysis research.

'This is another important collaboration for Angle with a leader in downstream analysis,' Angle chief executive Andrew Newland said.

'Abbott's PathVysion is the market leader for FISH evaluation of HER-2 in breast cancer. Following our FDA studies, we hope to be able to work with Abbott to extend PathVysion use into routine blood test analysis as an important downstream application of the Parsortix system in breast cancer.'

At 1:56pm: [LON:AGL] Angle PLC share price was -1.5p at 44.5p

Story provided by